TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01210170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo inhalation before albuterol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo inhalation before albuterol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo inhalation before albuterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 400 mcg
Description: mometasone inhalation before albuterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 400 mcg
Description: mometasone inhalation before albuterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 400 mcg
Description: mometasone inhalation before albuterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 200 mcg
Description: 200ug mometasone before albuterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 200 mcg
Description: 200ug mometasone before albuterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 200 mcg
Description: 200ug mometasone before albuterol.
Study: NCT01069172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS Laser Surgery
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CCC Surgery
Description: Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
Study: NCT03241199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: a first-generation tyrosine kinase inhibitors
Study: NCT01010633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Loteprednol Etabonate
Description: 1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: 1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
Study: NCT02558387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
Study: NCT02463071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: 1g soft capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: 1g soft capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585 placebo
Description: 1g soft capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD0585 placebo
Description: 1g soft capsule
Study: NCT01925898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam - active comparator
Description: Oral midazolam - 0.7mg/kg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm: Ketamine
Description: Oral Ketamine 5mg/kg Single dose
Study: NCT03086057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPare for Work: Strength Based Case Management (Stage 1)
Description: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPare for Work: Adherence Training and Counseling (Stage 2)
Description: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
Study: NCT03428022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Study: NCT03056950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DELFI PTS ii portable tourniquet
Description: A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
Study: NCT01195090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: add sitagliptin100mg/d to pre-study OADs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: add pioglitazone 30mg/d to pre-study OADs
Study: NCT04387955

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biological Sample Collection
Description: * Diagnostic test : biological sample collection at Day 0~* Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~* Anal swabbing at Day 0~* Blood test at Day 0~* Blood test at Month 1~* Blood test at Month 2
Study: NCT00888381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (2009 / 2010 formulation)
Description: A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (2009 / 2010 formulation)
Description: A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
Study: NCT01552655

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-time PET/CT (low-dose)
Description: 4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
Study: NCT02238951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health (mHealth)
Description: Participants receive care coordination throughout their chemotherapy treatment using mHealth technology

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No mHealth
Description: Participants receive the same evidence-based care coordination without mHealth technology
Study: NCT01093625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narafilcon B Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: spectacle wearers
Study: NCT02427230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal electrical stimulator (CefarPeristim Pro)
Description: electrical stimulation
Study: NCT02258503

Intervention type: OTHER
Intervention: pain in elderly patients

Intervention type: OTHER
Intervention: pain in elderly patients
Study: NCT03763669

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: myo-inositol (2 g. twice a day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for myoinositol)
Description: (twice a day)
Study: NCT01485341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten
Description: gluten is administered once a day at 10g/day for 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rice starch
Description: rice starch is administered once a day at 10 g/day for 15 days
Study: NCT02319291

Intervention type: DEVICE
Intervention: P.F.C. Sigma PS150 RP Total Knee System
Description: Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
Study: NCT01245387

Intervention type: DRUG
Intervention: Pegaptanib
Description: Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
Study: NCT02806154

Intervention type: OTHER
Intervention: DEXA
Description: The appendicular muscle mass measured by DEXA
Study: NCT02642016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-0158 (formerly known as KTN-0158)
Description: Single agent CDX-0158 until unacceptable toxicity or progressive disease
Study: NCT01523756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test product 1: new ostomy base plate with Coloplast as manufacturer
Description: test product 1 is tested first

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test product 2: new ostomy base plate with Coloplast as manufacturer
Description: test product 2 is tested first
Study: NCT02616744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronic acid
Description: 150 mg per month oral ibandronate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 oral capsule of placebo per month
Study: NCT04233164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol 1mg/kg
Description: Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol 250 mg
Description: Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 250 mg of methylprednisolone.
Study: NCT01423851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-018
Description: Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
Study: NCT01811745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze eurhythmics training
Description: 12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent exercise training
Description: 12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
Study: NCT05300321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frame lens
Description: The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frame lens
Description: The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
Study: NCT00570973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation
Description: Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS-Implantation
Description: Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
Study: NCT02232282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard acupuncture treatment
Description: A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Sham/Minimal Acupuncture
Description: Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints.
Study: NCT03351790

Intervention type: OTHER
Intervention: Questionniare only
Description: A pre-procedure questionnaire will be completed by all participants
Study: NCT00445484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT03520959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LV305
Description: Administered via subcutaneous (SC) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G305
Description: Administered via intramuscular (IM) injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LV305-matching placebo
Description: Administered via SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: G305-matching placebo
Description: Administered via IM injection.
Study: NCT03559036

Intervention type: PROCEDURE
Intervention: Locomotor Training
Description: Body-weight supported stepping on a treadmill.
Study: NCT03778567

Intervention type: DRUG
Group type: OTHER
Intervention: Telbivudine
Description: CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
Study: NCT02553122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evicel
Description: Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss

Intervention type: DEVICE
Group type: OTHER
Intervention: tourniquet
Description: A tourniquet is applied to the thigh to stop/ decrease blood flow
Study: NCT00998270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone marrow transplantation
Description: Autologous transplantation:~* Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~* G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~* Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Description: Allogeneic~* Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~* Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days
Study: NCT02132884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic procedure
Description: Receive standard of care treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted therapy
Description: Receive specific targeted therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01728415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
Study: NCT03922542

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
Study: NCT02525250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Realization of 3 Blood samples during study during treatment with lenalidomide
Study: NCT00626249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder
Description: Technosphere Inhalation Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder
Description: Technosphere Inhalation Powder
Study: NCT03959124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Brain stimulation electrodes at parameters 2.0\~4.5 V；60 μs；20 Hz

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical treatment for Alzheimer's disease
Description: Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment for Alzheimer's disease
Description: Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
Study: NCT02489136

Intervention type: OTHER
Group type: OTHER
Intervention: laying of hands (Spiritist passe)
Description: In a distance of 10 cm and to apply the spiritist passe for 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laying of hands (Spiritist passe)
Description: In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
Study: NCT03648008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.015 mg\*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
Study: NCT00560742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Coronary artery bypass grafting without bone marrow cells injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of bone marrow cells
Description: Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of bone marrow cells
Description: Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar